News | November 17, 2025
Lupin launches long-acting Risperidone in US
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
US Generics grew 5% to Rs. 467 Crores for the quarter
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
Stable profits, low leverage to keep credit profiles comfortable
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
Subscribe To Our Newsletter & Stay Updated
